Category: ACN Newswire

HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)

ROCKVILLE, MD and SHENZHEN, CHINA, June 21, 2024 – (ACN Newswire via – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will


JBM Healthcare Announces FY2024 Annual Results

KEY HIGHLIGHTS Year-on-year revenue increased by 24.6%, totalling HK$648.4 million Adjusted profit attributable to equity shareholders* soared 149.5% to HK$130.5 million The Board recommends a final dividend of HK4.05 cents per share All three business segments exhibited robust growth momentum


China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China

Innovative drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue®) is an oral diagnostic drug, approved by China’s NMPA for enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy. The results of the Phase III clinical trial in